Search for: "Alphapharm Pty. Ltd."
Results 1 - 20
of 49
Sorted by Relevance
|
Sort by Date
11 Dec 2008, 8:03 am
Alphapharm Pty., Ltd., 492 F.3d 1350 (Fed. [read post]
4 Jul 2007, 6:18 pm
By Donald Zuhn -- Last Thursday, the Federal Circuit upheld a judgment from a District Court that Defendant-Appellant Alphapharm Pty., Inc. had failed to prove invalidity and unenforceability of claims 1, 2, and 5 of U.S. [read post]
17 Dec 2008, 5:54 am
(Mylan) on the one hand, and Defendants-Appellants Alphapharm Pty., Inc. and Genpharm, Inc. [read post]
28 Jun 2007, 9:36 pm
Alphapharm Pty., Ltd., No. 06-1329 (Fed. [read post]
21 Apr 2013, 1:42 am
The omeprazole case went on to become a leading authority on the law of inventive step in Australia, after it was successfully appealed by Astra to the High Court of Australia (Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59). [read post]
28 Apr 2013, 8:08 am
Coincidentally, the High Court’s decision in Aktiebolaget Hässle v Alphapharm Pty Ltd [2002] HCA 59 is also the source of the current Australian law in relation to ‘obvious’ or ‘worthwhile’ to try (at paragraphs [66]-[76]). [read post]
27 Apr 2014, 4:16 am
And, it seems, rightly so – because on 11 April 2014 the High Court of Australia granted ‘special leave’ (transcript at Alphapharm Pty Ltd v H Lundbeck A/S & Ors [2014] HCATrans 79), allowing generic manufacturer Alphapharm Pty Ltd to appeal the Federal Court decision.In fact, Alphapharm was only 50% successful in its bid. [read post]
7 Nov 2014, 10:49 pm
The patent itself has already been found valid and infringed by a Full Bench of the Federal Court of Australia (in H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70), and all avenues of appeal from that decision have been exhausted. [read post]
11 Nov 2011, 5:18 am
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2011] FCAFC 132 (28 October 2011) Appeal from: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth Australia Pty Ltd [2010] FCA 1211 See also: Australian Federal Court Blocks Generic EFFEXOR-XR Validity – ‘external’ fair basis – whether claims entitled to priority date of original US application – whether claims are novel Generic pharmaceutical manufacturers Sigma… [read post]
21 Feb 2006, 10:13 pm
The consolidated defendants (Mylan Laboratories Inc, Mylan Pharmaceuticals, Inc., UDL Laboratories, Inc., Alphapharm Pty. [read post]
7 Sep 2011, 4:05 pm
The complaint alleges that Par Pharmaceuticals and two foreign companies - Alphapharm PTY Ltd. and Genpharm ULC - conspired with pharmacies to switch generic prescriptions to Par Pharmaceuticals’ generic version, allowing them to charge Medicaid higher prices. [read post]
24 Jun 2009, 10:17 am
The decision, H Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70, involves a decision of the Full Federal Court on rehearing an appeal by Alphapharm over an earlier decision regarding Lundbeck's Australian Patent No. 623144 for the antidepressant drug escitalopram. [read post]
28 May 2016, 7:13 pm
These were succinctly summarised by Justice Beach in Streetworx Pty Ltd v Artcraft Urban Group Pty Ltd [2014] FCA 1366 (a decision that was upheld on appeal) in the form of three questions:What has the patentee promised for the invention as described in the relevant claim? [read post]
3 Mar 2008, 9:27 pm
Alphapharm Pty., Ltd. [read post]
4 May 2014, 3:14 am
Specifically, in AstraZeneca AB v Alphapharm Pty Ltd [2014] FCA 419, the patentee has been awarded a higher level of attorney fees under section 19 of the Patents Act, which relates to Certificates of Validity. [read post]
1 Jul 2007, 11:53 pm
Alphapharm PTY., LTD., et al. [read post]
29 Jun 2007, 11:38 am
Alphapharm Pty., Ltd. after the jump. [read post]
30 Nov 2009, 1:19 am
Bitech Engineering v Garth Living Pty Ltd [2009] FCA 1393 [read post]
6 May 2009, 3:29 am
See now Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559 at [643]ff. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
